Raft of Japanese approvals includes Revolade and Byetta
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has issued formal final approvals for a large number of new products and additional indications, including GlaxoSmithKline's oral thrombopoietin receptor agonist Revolade (eltrombopag) and Lilly/Amylin's GLP-1 agonist Byetta (exenatide).